Clinical trial
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug…
NCT00268476 · Medical Research Council, Other · Active, not recruiting
Key facts
| NCT number | NCT00268476 |
|---|---|
| Title | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy |
| Official title | STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial |
| Acronym | STAMPEDE |
| Lead sponsor | Medical Research Council, Other |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Celecoxib, Docetaxel, Prednisolone, ADT, Zoledronic Acid, Abiraterone, Radiotherapy to the prostate, Enzalutamide, Metformin, Transdermal Oestradiol |
| Enrollment | 11,992 |
| Start date | Jul 8, 2005 |
| Primary completion | Mar 1, 2026 |
| Completion | Dec 1, 2030 |
| First posted | Dec 22, 2005 |
| Last update posted | Apr 18, 2023 |
| Countries | Switzerland, United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: